Stock Market
Hemostemix Revolutionizes Stem Cell Therapy Access with “Boots on the Ground” Strategy in Florida
Hemostemix Inc., a clinical-stage biotechnology company, is making headlines today with a bold new initiative aimed at expanding access to its autologous stem cell therapy, VesCell™ (ACP-01), across Florida under the state’s compassionate-use framework.
What’s New Today?
“Boots on the ground” initiative launched in Florida
Hemostemix has officially rolled out a face-to-face sales and outreach program in Miami, Naples, and Tampa. Spearheaded by CEO Thomas Smeenk and CCO Croom Lawrence, the team is engaging directly with podiatrists, cardiologists, vascular surgeons, and former Phase II trial investigators to build awareness and facilitate adoption of VesCell™ in clinics statewide.
Why It Matters
1. Regulatory Pathway Utilization
Florida’s SB 1768 right-to-try law allows Hemostemix to offer VesCell™ to patients with life-threatening or severely debilitating conditions who have exhausted standard-of-care options. This innovative approach enables patients to access cutting-edge treatments while Hemostemix gathers real-world evidence to support future FDA submissions.
2. Substantive Clinical Evidence
By August 2025, Hemostemix has treated 498 patients, completed seven clinical studies involving 318 subjects, and published findings across 11 peer-reviewed journals—all reinforcing VesCell™’s safety and efficacy in treating conditions like CLTI, angina, and various cardiomyopathies.
Clinical highlights include dramatic ulcer healing (from 1.46 cm² down to 0.48 mm² in three months, p = 0.01), improved cardiac function, and enhanced patient comfort and mobility.
3. Building Clinical Partnerships
Hemostemix’s engagement model emphasizes relationship-building: they’re not just promoting a treatment—they’re collaborating with clinicians who are familiar with ACP-01 from the trials. The aim is to foster trust, streamline adoption, and ensure rigorous data collection for later regulatory interaction.
Broader Context: Strategy Meets Execution
- Funding and Growth
Hemostemix has secured multiple rounds of financing, including a recent private placement, giving the company resources to drive commercialization in Florida and prepare for eventual FDA interaction. - Dual Purpose Rollout
The Florida initiative both generates revenue through compassionate-use treatments and builds a robust evidence base for regulators—reinforcing Hemostemix’s long-term strategy.
Suggested Headlines to Raise Awareness
- Hemostemix Brings Stem Cell Therapy to Florida: “Boots on the Ground” Initiative Takes VesCell™ Directly to Clinics
- Autologous Stem Cell Access in Action: Hemostemix Engages Florida Clinicians to Transform Care for No-Option Patients
- From Trials to Treatment: Hemostemix’s On-the-Ground Strategy in Florida Sets Stage for Broader Approval
Why This Announcement Matters — In Short
- Patients: Offers new hope to individuals with severe, otherwise untreatable conditions.
- Clinicians: Provides direct access to a promising therapy and support for implementation.
- Investors: Demonstrates tactical commercialization with regulatory foresight and clinical validation.
- Industry: Signals a novel model for balancing compassionate use with evidence generation in biomedicine.
Sources
Disclosure: Lusso’s News, LLC(“EMV”) has been compensated by Hemostemix Inc. (“Hemostemix”) in the amount of $5,000 USD per month, commencing August 13, 2025, and continuing through September 31, 2025, with the possibility of extension until further notice. This compensation is for the creation and dissemination of content about Hemostemix, including but not limited to articles, website postings, social media updates, and other promotional materials.
The content produced by EMV is intended solely for informational purposes. It does not constitute an offer to sell, a solicitation to buy, or a recommendation regarding any security, investment product, or trading strategy. EMV is not a registered investment adviser or broker-dealer, and nothing in this content should be construed as personalized investment advice.
Investing in securities involves risks, including the potential loss of principal. Readers should conduct their own independent research, perform due diligence, and consult with a licensed financial adviser, attorney, or tax professional before making any investment decisions.
EMV’s compensation from Hemostemix presents a conflict of interest as EMV has a financial incentive to promote Hemostemix. As a result, the content may be biased and should not be relied upon as independent or impartial.
By accessing this content or the associated website, you acknowledge and agree to the terms of this disclaimer.